Synthetic peptides deduced from the amino acid sequence of Epstein‐Barr virus nuclear antigen 6 (EBNA 6): Antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man

K. Falk, A. Linde, D. Johnson, E. Lennette, I. Ernberg, A. Lundkvist

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Studies on the antibody responses to various Epstein‐Barr virus (EBV) antigens have been instrumental in the understanding of the seroepidemiology and diagnosis of this viral infection and the subsequent carrier state. While antibodies to the viral capsid antigen (VCA), early antigen (EA), and nuclear antigens 1 and 2 (EBNA 1 and 2) have been well characterized, the antibody response to the other nuclear antigens is not well understood. EBNA 6 is expressed by lymphoblasts during acute EBV infection and may be an important antigen for diagnosis and evaluation of the immune response. In order to analyze the antibody response to EBNA 6, ten peptides (20–21 amino acids), deduced from the EBNA 6 coding region, were synthesized and evaluated for antigenicity by ELISA. One peptide (p‐63; PA‐PQAPYQGYQEPPAPQAPY) derived from the amino acid repeats showed the highest specific reactivity with human sera. This peptide was evaluated further for detection of human EBNA 6‐reactive antibodies. Forty‐two of forty‐nine (86%) EBV‐seropositive healthy donors had p‐63‐ specific IgG reactivity, while none of 50 EBV seronegative patients reacted with the p‐63 peptide. Twenty‐two of fifty‐one (43%) patients with ongoing primary EBV infection had detectable p‐63‐specific IgG. Serum samples drawn sequentially from patients during and after primary EBV infection revealed an increase in p‐63‐reactive IgG over time. A similar pattern was found for reactivity with an EBNA I‐specific peptide (p‐107), in contrast to the EBNA 2 (polyproline) response, which decreased over time. Some EBV seropositive individuals who had no detectable IgG against peptide p‐63 did have antibodies against the native EBNA 6 by anticomplement immunofluorescence to EBNA 6 transfected cells. Rabbit antiserum raised against p‐63 reacted specifically with native EBNA 6 by an immunofluorescence assay and by immunoblotting, indicating the EBNA 6‐specific antigenicity of the peptide. Thus, the peptide p‐63 derived from the amino acid repeats of the EBNA 6 coding region constitutes a predominant, although not exclusive, epitope in the EBNA 6 antibody response. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)349-357
Number of pages9
JournalJournal of Medical Virology
Volume46
Issue number4
DOIs
StatePublished - Aug 1995

Fingerprint

Nuclear Antigens
Antibody Formation
Amino Acid Sequence
Viruses
Peptides
Virus Diseases
Immunoglobulin G
Antigens
Amino Acids
Fluorescent Antibody Technique
Antibodies
Carrier State
Viral Antigens
Capsid
Serum
Immunoblotting
Immune Sera
Epitopes
Enzyme-Linked Immunosorbent Assay
Tissue Donors

Keywords

  • EBNA 6 peptide
  • EBV nuclear antigen
  • epitope ELSA

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Synthetic peptides deduced from the amino acid sequence of Epstein‐Barr virus nuclear antigen 6 (EBNA 6) : Antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man. / Falk, K.; Linde, A.; Johnson, D.; Lennette, E.; Ernberg, I.; Lundkvist, A.

In: Journal of Medical Virology, Vol. 46, No. 4, 08.1995, p. 349-357.

Research output: Contribution to journalArticle

@article{2ff79ed720284b6f8899d6539854fcd0,
title = "Synthetic peptides deduced from the amino acid sequence of Epstein‐Barr virus nuclear antigen 6 (EBNA 6): Antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man",
abstract = "Studies on the antibody responses to various Epstein‐Barr virus (EBV) antigens have been instrumental in the understanding of the seroepidemiology and diagnosis of this viral infection and the subsequent carrier state. While antibodies to the viral capsid antigen (VCA), early antigen (EA), and nuclear antigens 1 and 2 (EBNA 1 and 2) have been well characterized, the antibody response to the other nuclear antigens is not well understood. EBNA 6 is expressed by lymphoblasts during acute EBV infection and may be an important antigen for diagnosis and evaluation of the immune response. In order to analyze the antibody response to EBNA 6, ten peptides (20–21 amino acids), deduced from the EBNA 6 coding region, were synthesized and evaluated for antigenicity by ELISA. One peptide (p‐63; PA‐PQAPYQGYQEPPAPQAPY) derived from the amino acid repeats showed the highest specific reactivity with human sera. This peptide was evaluated further for detection of human EBNA 6‐reactive antibodies. Forty‐two of forty‐nine (86{\%}) EBV‐seropositive healthy donors had p‐63‐ specific IgG reactivity, while none of 50 EBV seronegative patients reacted with the p‐63 peptide. Twenty‐two of fifty‐one (43{\%}) patients with ongoing primary EBV infection had detectable p‐63‐specific IgG. Serum samples drawn sequentially from patients during and after primary EBV infection revealed an increase in p‐63‐reactive IgG over time. A similar pattern was found for reactivity with an EBNA I‐specific peptide (p‐107), in contrast to the EBNA 2 (polyproline) response, which decreased over time. Some EBV seropositive individuals who had no detectable IgG against peptide p‐63 did have antibodies against the native EBNA 6 by anticomplement immunofluorescence to EBNA 6 transfected cells. Rabbit antiserum raised against p‐63 reacted specifically with native EBNA 6 by an immunofluorescence assay and by immunoblotting, indicating the EBNA 6‐specific antigenicity of the peptide. Thus, the peptide p‐63 derived from the amino acid repeats of the EBNA 6 coding region constitutes a predominant, although not exclusive, epitope in the EBNA 6 antibody response. {\circledC} 1995 Wiley‐Liss, Inc.",
keywords = "EBNA 6 peptide, EBV nuclear antigen, epitope ELSA",
author = "K. Falk and A. Linde and D. Johnson and E. Lennette and I. Ernberg and A. Lundkvist",
year = "1995",
month = "8",
doi = "10.1002/jmv.1890460410",
language = "English (US)",
volume = "46",
pages = "349--357",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Synthetic peptides deduced from the amino acid sequence of Epstein‐Barr virus nuclear antigen 6 (EBNA 6)

T2 - Antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man

AU - Falk, K.

AU - Linde, A.

AU - Johnson, D.

AU - Lennette, E.

AU - Ernberg, I.

AU - Lundkvist, A.

PY - 1995/8

Y1 - 1995/8

N2 - Studies on the antibody responses to various Epstein‐Barr virus (EBV) antigens have been instrumental in the understanding of the seroepidemiology and diagnosis of this viral infection and the subsequent carrier state. While antibodies to the viral capsid antigen (VCA), early antigen (EA), and nuclear antigens 1 and 2 (EBNA 1 and 2) have been well characterized, the antibody response to the other nuclear antigens is not well understood. EBNA 6 is expressed by lymphoblasts during acute EBV infection and may be an important antigen for diagnosis and evaluation of the immune response. In order to analyze the antibody response to EBNA 6, ten peptides (20–21 amino acids), deduced from the EBNA 6 coding region, were synthesized and evaluated for antigenicity by ELISA. One peptide (p‐63; PA‐PQAPYQGYQEPPAPQAPY) derived from the amino acid repeats showed the highest specific reactivity with human sera. This peptide was evaluated further for detection of human EBNA 6‐reactive antibodies. Forty‐two of forty‐nine (86%) EBV‐seropositive healthy donors had p‐63‐ specific IgG reactivity, while none of 50 EBV seronegative patients reacted with the p‐63 peptide. Twenty‐two of fifty‐one (43%) patients with ongoing primary EBV infection had detectable p‐63‐specific IgG. Serum samples drawn sequentially from patients during and after primary EBV infection revealed an increase in p‐63‐reactive IgG over time. A similar pattern was found for reactivity with an EBNA I‐specific peptide (p‐107), in contrast to the EBNA 2 (polyproline) response, which decreased over time. Some EBV seropositive individuals who had no detectable IgG against peptide p‐63 did have antibodies against the native EBNA 6 by anticomplement immunofluorescence to EBNA 6 transfected cells. Rabbit antiserum raised against p‐63 reacted specifically with native EBNA 6 by an immunofluorescence assay and by immunoblotting, indicating the EBNA 6‐specific antigenicity of the peptide. Thus, the peptide p‐63 derived from the amino acid repeats of the EBNA 6 coding region constitutes a predominant, although not exclusive, epitope in the EBNA 6 antibody response. © 1995 Wiley‐Liss, Inc.

AB - Studies on the antibody responses to various Epstein‐Barr virus (EBV) antigens have been instrumental in the understanding of the seroepidemiology and diagnosis of this viral infection and the subsequent carrier state. While antibodies to the viral capsid antigen (VCA), early antigen (EA), and nuclear antigens 1 and 2 (EBNA 1 and 2) have been well characterized, the antibody response to the other nuclear antigens is not well understood. EBNA 6 is expressed by lymphoblasts during acute EBV infection and may be an important antigen for diagnosis and evaluation of the immune response. In order to analyze the antibody response to EBNA 6, ten peptides (20–21 amino acids), deduced from the EBNA 6 coding region, were synthesized and evaluated for antigenicity by ELISA. One peptide (p‐63; PA‐PQAPYQGYQEPPAPQAPY) derived from the amino acid repeats showed the highest specific reactivity with human sera. This peptide was evaluated further for detection of human EBNA 6‐reactive antibodies. Forty‐two of forty‐nine (86%) EBV‐seropositive healthy donors had p‐63‐ specific IgG reactivity, while none of 50 EBV seronegative patients reacted with the p‐63 peptide. Twenty‐two of fifty‐one (43%) patients with ongoing primary EBV infection had detectable p‐63‐specific IgG. Serum samples drawn sequentially from patients during and after primary EBV infection revealed an increase in p‐63‐reactive IgG over time. A similar pattern was found for reactivity with an EBNA I‐specific peptide (p‐107), in contrast to the EBNA 2 (polyproline) response, which decreased over time. Some EBV seropositive individuals who had no detectable IgG against peptide p‐63 did have antibodies against the native EBNA 6 by anticomplement immunofluorescence to EBNA 6 transfected cells. Rabbit antiserum raised against p‐63 reacted specifically with native EBNA 6 by an immunofluorescence assay and by immunoblotting, indicating the EBNA 6‐specific antigenicity of the peptide. Thus, the peptide p‐63 derived from the amino acid repeats of the EBNA 6 coding region constitutes a predominant, although not exclusive, epitope in the EBNA 6 antibody response. © 1995 Wiley‐Liss, Inc.

KW - EBNA 6 peptide

KW - EBV nuclear antigen

KW - epitope ELSA

UR - http://www.scopus.com/inward/record.url?scp=0029081333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029081333&partnerID=8YFLogxK

U2 - 10.1002/jmv.1890460410

DO - 10.1002/jmv.1890460410

M3 - Article

C2 - 7595412

AN - SCOPUS:0029081333

VL - 46

SP - 349

EP - 357

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 4

ER -